EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Macugen

pegaptanib

Table of contents

WITHDRAWN
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Macugen has been withdrawn at the request of the marketing-authorisation holder.

Macugen : EPAR - Summary for the public (PDF/520.99 KB)

First published: 31/05/2007
Last updated: 27/06/2019

Available languages (21)

More detail is available in the summary of product characteristics

This EPAR was last updated on 27/06/2019

Authorisation details

Name
Macugen

Agency product number

EMEA/H/C/000620

Active substance

pegaptanib

International non-proprietary name (INN) or common name

pegaptanib

Therapeutic area (MeSH)

Wet Macular Degeneration

Anatomical therapeutic chemical (ATC) code

S01LA03

Marketing-authorisation holder

PharmaSwiss Ceska Republika s.r.o

Revision

15

Date of issue of marketing authorisation valid throughout the European Union

31/01/2006

Contact address

Jankovcova 1569/2c
Lighthouse
17000 Prague 7
Czech Republic

Product information

20/07/2016 Macugen - EMEA/H/C/000620 - IB/0065

Macugen : EPAR - Product Information (PDF/832.53 KB)

First published: 03/08/2009
Last updated: 27/06/2019

Available languages (24)

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Macugen : EPAR - All Authorised presentations (PDF/457.96 KB)

First published: 05/02/2008
Last updated: 27/06/2019

Available languages (21)

Macugen : EPAR - Conditions imposed on member states for safe and effective use - Annex IV (PDF/477.37 KB)

First published: 13/07/2007
Last updated: 27/06/2019

Available languages (21)

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Assessment history

Changes since initial authorisation of medicine

Macugen : EPAR - Procedural steps taken and scientific information after authorisation (PDF/688.92 KB)

First published: 03/08/2009
Last updated: 27/06/2019

Initial marketing-authorisation documents

Macugen : EPAR - Procedural steps taken before authorisation (PDF/482.92 KB)

First published: 31/05/2007
Last updated: 27/06/2019

Macugen : EPAR - Scientific Discussion (PDF/984.11 KB)

First published: 31/05/2007
Last updated: 27/06/2019

More information on Macugen

Related content

- Macugen: Withdrawn application
- Macugen: Paediatric investigation plan

CONTACT

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us

Postal address and deliveries

Business hours and holidays

An agency of the European Union